Zoetis (NYSE:ZTS) FY Conference Transcript

Summary of Zoetis Conference Call Company Overview - Company: Zoetis - Industry: Animal Health Key Financial Performance - Fiscal Year 2025: - Top line growth of 6% on an organic operational basis - Bottom line growth of 7% - Growth was 9% in the first half and 6% in the second half of the year [4][5] - Fiscal Year 2026 Guidance: - Expected top line growth between 3% and 5% - Expected bottom line growth between 3% and 6% [5][6] Market Dynamics - Consumer Behavior: - Weakness observed in the U.S. consumer market, particularly affecting pet care - Consumers are spending more on animal health, but this is driven by higher prices rather than volume [5][9] - Livestock Portfolio: - Continued strong growth in livestock, with growth rates of 6%, 5%, and 7% over the past three years - Expected to grow in the mid-single digits in 2026, outpacing companion animal growth [5][6][16] Competitive Landscape - Pet Care Market: - Competitive dynamics have impacted growth, particularly in the second half of 2025 - Price increases have affected Gen Z and millennials, leading to reduced volume [7][9] - International Business: - International companion animal business has shown growth similar to the U.S. market - Significant opportunities exist in international markets, particularly in livestock [14][15] Product Segments - Parasiticides: - Global market size of nearly $7 billion - Triple combination products have gained significant market share, now accounting for 50% of U.S. clinic patient share [25][26][28] - Trio product generated $1 billion in revenues in the U.S. last year [28] - Dermatology: - Revenues reached $1.7 billion in 2025, with room for further expansion - Competitive pressures and a decrease in therapeutic visits impacted growth in the second half of 2025 [42][43] Pipeline and Future Growth - Pipeline Focus: - Key areas include chronic kidney disease, oncology, cardiology, and obesity, representing a $7 billion total addressable market opportunity [53] - Ongoing R&D efforts to expand existing markets and address unmet needs in animal health [54][55] Capital Allocation Strategy - Investment Priorities: - Focus on investing in the business, including R&D and M&A - Share repurchase program remains a priority, with $2.4 billion remaining on the authorization [62][63] Conclusion - Outlook for 2026: - Despite headwinds, Zoetis remains optimistic about growth opportunities in both the companion and livestock segments - The company is well-positioned to leverage its product pipeline and market leadership to drive future growth [66][67]